Lung cancer and regular use of aspirin and nonaspirin nonsteroidal anti-inflammatory drugs

Authors

  • Judith P. Kelly RN, MS,

    Corresponding author
    1. Slone Epidemiology Center of Boston University, Boston, MA, USA
    • Slone Epidemiology Center, 1010 Commonwealth Ave., Boston, MA 02215, USA.
    Search for more papers by this author
  • Patricia Coogan DSc,

    1. Slone Epidemiology Center of Boston University, Boston, MA, USA
    Search for more papers by this author
  • Brian L. Strom MD, MPH,

    1. Center for Clinical Epidemiology and Biostatistics, Department of Biostatistics and Epidemiology, Center for Education and Research on Therapeutics, and Division of General Internal Medicine of the Department of Medicine, University of Pennsylvania School of Medicine, Philadelphia, PA, USA
    Search for more papers by this author
  • Lynn Rosenberg ScD

    1. Slone Epidemiology Center of Boston University, Boston, MA, USA
    Search for more papers by this author

  • No conflict of interest was declared.

Abstract

Purpose

Lung cancer is the leading cause of cancer death in the US. There is evidence of a reduced risk of some cancer sites associated with use of aspirin (ASA) and nonaspirin nonsteroidal anti-inflammatory drugs (NANSAIDs). Our objective was to examine the association of regular use of ASA and NANSAIDs with lung cancer.

Methods

A hospital-based case–control study of 1884 incident cases of lung cancer and 6251 controls with noncancer diagnoses. Use of ASA and NANSAIDs was considered ‘regular’ if it occurred on ≥4 days/week and lasted for ≥3 months. Logistic regression was used to estimate odds ratios (OR) and 95% confidence intervals.

Results

The OR for regular use of ASA was 1.1 (0.9–1.4), and the corresponding estimate for regular NANSAID use was 1.0 (0.7–1.3). There was no evidence of decreased risk within strata of age, sex, years of education, or interview year. Examining the association within strata of duration of use, recency of use, cigarette smoking status, pack-years of cigarette smoking, or histologic type of cancer produced no ORs significantly different from 1.0.

Conclusions

The hypothesis that regular use of ASA or NANSAIDs reduces the risk of lung cancer is not supported by the present data. Copyright © 2007 John Wiley & Sons, Ltd.

Ancillary